Trial Profile
A Phase I, Randomized, Double-Blind, Four-way Cross-over Study in Healthy Subjects to Assess Quantitative Electroencephalography (qEEG) Parameters After the Administration of Ketamine, Two Doses of AZD6765 and Placebo
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 25 Jun 2014
Price :
$35
*
At a glance
- Drugs Lanicemine (Primary) ; Ketamine
- Indications Depressive disorders
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 25 Jun 2014 New trial record